ScholarIQanswers from OpenAlex & ORCID
Noboru Yamamoto
ResearcherPublications, citations & collaboration network
Noboru Yamamoto is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Noboru Yamamoto have?
ScholarIQindexed works
Noboru Yamamoto has 1,233 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Noboru Yamamoto have?
ScholarIQcitation count
Noboru Yamamoto has 18,456 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Noboru Yamamoto?
ScholarIQh-index
Noboru Yamamoto has an h-index of 67 in OpenAlex.
What is the i10-index of Noboru Yamamoto?
ScholarIQi10-index
Noboru Yamamoto has an i10-index of 320 in OpenAlex.
What is the ORCID of Noboru Yamamoto?
ScholarIQorcid
The ORCID for Noboru Yamamoto is on the source record.
What is the OpenAlex record for Noboru Yamamoto?
ScholarIQopenalex
The OpenAlex for Noboru Yamamoto is on the source record.
What are the most-cited papers on Noboru Yamamoto?
ScholarIQmost cited works
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto, Nobuyuki Yamamoto
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Kōichi Goto
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander I. Spira, Edward B. Garon, Satoru Kitazono, Melissa L. Johnson, Funda Meric‐Bernstam, Anthony W. Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger‐Gong, Fumiaki Kobayashi, Penny Phillips, Aaron Lisberg, Rebecca S. Heist
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Kazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Taizo Hirata, Fumiaki Koizumi, Kazuto Nishio, Noriyuki Koyama, Tomohide Tamura